- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 13, 2023
Deals
June 12 Quick Takes: AZ’s first-in-class AKT inhibitor under review
Plus: Simcere grows Massachusetts presence, and updates from Eisai, Bliss, Eccogene, Phathom, Ironwood and more
BioCentury | Jun 1, 2023
Data Byte
At least 15 PDUFA dates on FDA’s calendar for June
Expected decisions include BioMarin’s hemophilia A gene therapy, a subQ form of argenx’s of myasthenia gravis drug, and Aldeyra’s retinal cancer candidate
BioCentury | May 23, 2023
Deals
Sizing up VectivBio’s takeout premium among '23 M&A deals
Many companies with late-stage assets have commanded triple-digit premiums
BioCentury | Apr 21, 2023
Product Development
ADC advances at AACR: target diversity, optimizing internalization
BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | Dec 3, 2022
Finance
Dec. 2 Quick Takes: Liminatus heads for NASDAQ via SPAC deal
Plus: FDA clears Beam’s CD7-targeting CAR T for clinical trial, and updates from GSK, Theratechnologies, PictorLabs and more
BioCentury | Sep 9, 2022
Product Development
China driving solid tumor CAR T innovation
Chinese investigator-initiated trials are accelerating CAR T innovation, bringing solid tumor advances to ESMO22
BioCentury | Feb 18, 2022
Product Development
Feb. 17 Quick Takes: Agios wins FDA approval in rare anemia
Plus updates from Arvinas, BMS, Innovent, Ironwood, Deerfield, Yumanity
Items per page:
1 - 10 of 205